IMUNON Announces Transition in Financial Leadership
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: seekingalpha
- Leadership Transition: IMUNON announced the retirement of Jeffrey Church as interim CFO effective July 1, 2026, with Josh Blacher stepping in, demonstrating the company's commitment to stable financial management.
- Advisory Role Continuation: Church will continue to support the company in an advisory capacity under an amended consulting agreement, receiving a monthly retainer of $10,000, ensuring a smooth leadership transition.
- Rich Industry Experience: Blacher enters his new role through a master services agreement with Danforth Health, Inc., bringing extensive expertise from his previous CFO positions at multiple Nasdaq-listed companies to IMUNON.
- Transparent Service Fees: Under the agreement with Danforth Health, IMUNON will pay Blacher $475 per hour for his services, ensuring financial transparency and avoiding any conflicts of interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMNN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMNN
Wall Street analysts forecast IMNN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.880
Low
12.00
Averages
12.00
High
12.00
Current: 1.880
Low
12.00
Averages
12.00
High
12.00
About IMNN
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IMUNON Announces Transition in Financial Leadership
- Leadership Transition: IMUNON announced the retirement of Jeffrey Church as interim CFO effective July 1, 2026, with Josh Blacher stepping in, demonstrating the company's commitment to stable financial management.
- Advisory Role Continuation: Church will continue to support the company in an advisory capacity under an amended consulting agreement, receiving a monthly retainer of $10,000, ensuring a smooth leadership transition.
- Rich Industry Experience: Blacher enters his new role through a master services agreement with Danforth Health, Inc., bringing extensive expertise from his previous CFO positions at multiple Nasdaq-listed companies to IMUNON.
- Transparent Service Fees: Under the agreement with Danforth Health, IMUNON will pay Blacher $475 per hour for his services, ensuring financial transparency and avoiding any conflicts of interest.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Virtual Investor Conferences Forum Highlights
- On-Demand Presentations: The Life Sciences Virtual Investor Forum held on June 24-25, 2026, is now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- Company Participation: Companies such as MetaVia Inc. (NASDAQ: MTVA) and CytoSorbents Corporation (NASDAQ: CTSO) are accepting one-on-one management meeting requests, facilitating direct communication between investors and management teams.
- Investor Materials Access: Attendees can download investor materials from the companies' resource sections, which not only increases transparency but also provides potential investors with essential decision-making support.
- Interactive Platform Benefits: Virtual Investor Conferences offer real-time investor engagement solutions that replicate the components of on-site conferences, improving the efficiency of connections between companies and investors, thereby fostering stronger investor relations.
See More
Agenda Announced for Life Sciences Virtual Investor Forum
- Forum Schedule: The Life Sciences Virtual Investor Forum, taking place on June 24-25, 2026, will bring together innovators from various companies, providing an efficient platform for direct engagement between investors and companies, expected to attract numerous individual and institutional investors.
- Easy Participation: Investors can register for free and run an online system check to expedite participation and receive event updates, with live company presentations and one-on-one meeting arrangements enhancing the investor experience during the forum.
- Company Showcase: The forum will feature multiple publicly traded companies, including MetaVia Inc. and CytoSorbents Corporation, covering various life sciences sectors, which is expected to provide investors with rich industry insights and investment opportunities.
- Investor Relations Enhancement: Virtual Investor Conferences aim to improve communication efficiency between companies and investors by offering real-time interactive engagement solutions, helping companies better showcase their strategies and business development plans.
See More
IMUNON CEO to Present at Life Sciences Investor Forum
- Investor Forum Presentation: IMUNON's CEO, Dr. Stacy Lindborg, will present at the Life Sciences Investor Forum on June 25, 2026, at 12:00 p.m. ET, which is expected to draw significant investor interest in its clinical-stage DNA-mediated immunotherapy.
- Clinical Trial Progress: The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer currently in Phase 3 trials (OVATION 3), which may establish a strong foundation for future market potential.
- Technological Innovation: IMUNON's non-viral DNA technology includes TheraPlas® for cytokine delivery and PlaCCine® for viral antigen delivery, showcasing innovative potential in treating difficult-to-treat conditions.
- COVID-19 Vaccine Research: The company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101), further demonstrating its capabilities in vaccine development and potentially supporting future product line expansion.
See More
IMUNON Secures $10 Million Financing for Clinical Trials
- Financing Agreement: IMUNON has entered into definitive agreements for total gross proceeds of $10 million, which includes 250 shares of non-convertible preferred stock for $2.5 million and two secured promissory notes totaling $7.72 million.
- Interest Rates and Maturity: The promissory notes carry interest rates of 8% and 5% per annum, maturing 18 months post-issuance, with IMUNON planning to use the net proceeds to support its pivotal Phase 3 OVATION 3 clinical trial.
- Clinical Trial Progress: The OVATION 3 trial is evaluating the efficacy of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy for newly diagnosed advanced ovarian cancer patients, with IMNN-001 being a DNA-based immunotherapy aimed at localized treatment.
- Stock Performance: IMUNON's stock has traded between $2.04 and $27.65 over the past year, closing at $2.10 on Thursday with a 0.97% increase, and rising 1.43% to $2.13 in after-hours trading, reflecting positive market sentiment towards its financing and clinical advancements.
See More
IMUNON Announces Transition in Financial Leadership
- Leadership Transition: IMUNON announced the retirement of Jeffrey Church as interim CFO effective July 1, 2026, with Josh Blacher stepping in, demonstrating the company's commitment to stable financial management.
- Advisory Role Continuation: Church will continue to support the company in an advisory capacity under an amended consulting agreement, receiving a monthly retainer of $10,000, ensuring a smooth leadership transition.
- Rich Industry Experience: Blacher enters his new role through a master services agreement with Danforth Health, Inc., bringing extensive expertise from his previous CFO positions at multiple Nasdaq-listed companies to IMUNON.
- Transparent Service Fees: Under the agreement with Danforth Health, IMUNON will pay Blacher $475 per hour for his services, ensuring financial transparency and avoiding any conflicts of interest.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Virtual Investor Conferences Forum Highlights
- On-Demand Presentations: The Life Sciences Virtual Investor Forum held on June 24-25, 2026, is now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- Company Participation: Companies such as MetaVia Inc. (NASDAQ: MTVA) and CytoSorbents Corporation (NASDAQ: CTSO) are accepting one-on-one management meeting requests, facilitating direct communication between investors and management teams.
- Investor Materials Access: Attendees can download investor materials from the companies' resource sections, which not only increases transparency but also provides potential investors with essential decision-making support.
- Interactive Platform Benefits: Virtual Investor Conferences offer real-time investor engagement solutions that replicate the components of on-site conferences, improving the efficiency of connections between companies and investors, thereby fostering stronger investor relations.
See More
Agenda Announced for Life Sciences Virtual Investor Forum
- Forum Schedule: The Life Sciences Virtual Investor Forum, taking place on June 24-25, 2026, will bring together innovators from various companies, providing an efficient platform for direct engagement between investors and companies, expected to attract numerous individual and institutional investors.
- Easy Participation: Investors can register for free and run an online system check to expedite participation and receive event updates, with live company presentations and one-on-one meeting arrangements enhancing the investor experience during the forum.
- Company Showcase: The forum will feature multiple publicly traded companies, including MetaVia Inc. and CytoSorbents Corporation, covering various life sciences sectors, which is expected to provide investors with rich industry insights and investment opportunities.
- Investor Relations Enhancement: Virtual Investor Conferences aim to improve communication efficiency between companies and investors by offering real-time interactive engagement solutions, helping companies better showcase their strategies and business development plans.
See More
IMUNON CEO to Present at Life Sciences Investor Forum
- Investor Forum Presentation: IMUNON's CEO, Dr. Stacy Lindborg, will present at the Life Sciences Investor Forum on June 25, 2026, at 12:00 p.m. ET, which is expected to draw significant investor interest in its clinical-stage DNA-mediated immunotherapy.
- Clinical Trial Progress: The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer currently in Phase 3 trials (OVATION 3), which may establish a strong foundation for future market potential.
- Technological Innovation: IMUNON's non-viral DNA technology includes TheraPlas® for cytokine delivery and PlaCCine® for viral antigen delivery, showcasing innovative potential in treating difficult-to-treat conditions.
- COVID-19 Vaccine Research: The company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101), further demonstrating its capabilities in vaccine development and potentially supporting future product line expansion.
See More
IMUNON Secures $10 Million Financing for Clinical Trials
- Financing Agreement: IMUNON has entered into definitive agreements for total gross proceeds of $10 million, which includes 250 shares of non-convertible preferred stock for $2.5 million and two secured promissory notes totaling $7.72 million.
- Interest Rates and Maturity: The promissory notes carry interest rates of 8% and 5% per annum, maturing 18 months post-issuance, with IMUNON planning to use the net proceeds to support its pivotal Phase 3 OVATION 3 clinical trial.
- Clinical Trial Progress: The OVATION 3 trial is evaluating the efficacy of IMNN-001 in combination with neoadjuvant and adjuvant chemotherapy for newly diagnosed advanced ovarian cancer patients, with IMNN-001 being a DNA-based immunotherapy aimed at localized treatment.
- Stock Performance: IMUNON's stock has traded between $2.04 and $27.65 over the past year, closing at $2.10 on Thursday with a 0.97% increase, and rising 1.43% to $2.13 in after-hours trading, reflecting positive market sentiment towards its financing and clinical advancements.
See More
